Clinical Trials Directory

Trials / Completed

CompletedNCT01941602

A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery

A Comparative Study of Prophylactic Enoxaparin Routinely Administered Preoperative for Prevention of Venous Thromboembolism in Meningioma Surgery - an Acceptable Risk-benefit Ratio?

Status
Completed
Phase
Study type
Observational
Enrollment
979 (actual)
Sponsor
St. Olavs Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of the study is to compare different strategies for prevention of venous thromboembolism related to intracranial meningioma surgery. The investigators identified three hospitals where two have a very restrictive approach with respect to anticoagulant therapy while at the third hospital the use of anticoagulation the day before surgery was initiated as routine prophylaxis. Based on this "natural experiment" it will be explored whether the use of anticoagulant prophylaxis is associated with reduced risk of venous thromboembolism and/or associated with increased risk of postoperative hemorrhage as compared to the 2 cohorts where this intervention were absent.

Conditions

Interventions

TypeNameDescription
DRUGprophylactic enoxaparinenoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
PROCEDUREnon-prophylacticno pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.

Timeline

Start date
2013-08-01
Primary completion
2015-10-01
Completion
2015-10-01
First posted
2013-09-13
Last updated
2017-10-02

Locations

3 sites across 2 countries: Norway, Sweden

Source: ClinicalTrials.gov record NCT01941602. Inclusion in this directory is not an endorsement.